Evolysse™ is now an award-winning injectable HA! Named “Best Dermal Filler 2025” by Shape Magazine, we’re proudly evolving the category and conversation, dropping the F word in favor of “injectable hyaluronic acid.” Innovative Cold-X™ Technology helps achieve natural looking results patients – and press – are already raving about. Check us out: https://lnkd.in/e7PUSskD
At Evolus, we commit to reach beyond our roles. We move quickly but also have enough time and space to generate beautiful, innovative ideas. Nobody will hold you back here. Your voice matters. We celebrate that creating impact is unique to each of us - and your impact will be yours to own. Want to create impact? Join our performance beauty movement. #evolus #performancebeauty #evolvewithus US-UNB-2500156
The aesthetics industry has used the same language for years, but Evolus is changing the conversation. Our #DropTheFWord campaign is hard hitting with a strong push to transition the category away from the use of ‘fillers’ and into the incredible world of injectable HA gels. With the first advance in HA technology in a decade, Evolysse™ isn’t just another filler, it’s the future of performance beauty. It’s time to drop the F word. #Evolysse #Evolus #EvolveWithUs
We’re excited to share we’ve chosen Milan as the home of our Evolus International HQ! Milan is the perfect fit for Evolus as a performance beauty company. It’s a vibrant business and cultural hub with a thriving ecosystem in design and beauty. Milan offers access to top talent and has great connections to Europe and beyond. These qualities align perfectly with who we are and how we operate. The decision to establish an Evolus International HQ reflects our rapid growth, our commitment to global expansion and our belief that we are building something truly special. Our new HQ will reflect our cultural values, fostering collaboration and a shared sense of purpose to elevate performance beauty on the world stage. We want our customers to experience our values firsthand. Our success is built on clinical and medical education. That’s why our International HQ will also feature facilities allowing for cutting-edge scientific exchange and hands-on collaboration between employees and customers. Stay tuned as we create a world-class hub that reflects our culture of grit, impact, fun and transparency! Ciao Milano. Evolve with us. #evolus #performancebeauty #evolvewithus
Our General Counsel Jeff Plumer recently won General Counsel Of The Year For A Public Company by the Orange County Business Journal. Jeff’s leadership and strategic guidance have been instrumental in shaping our success and navigating the landscape of the aesthetics industry. We’re proud to have him on our team and thrilled to see his exceptional work recognized! @ocbizjournal #evolus #performancebeauty #medicalaesthetics US-UNB-2400422
Evolus has achieved a major milestone with FDA approval of Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, marking our entry into the U.S. HA dermal filler market. This technological breakthrough expands our addressable market by 78% and accelerates our transformation into a multi-product leader in #performance beauty. Evolysse™ introduces the first major #innovation in injectable HA dermal fillers in a decade, powered by SYMATESE’s Cold-X™ technology for long-lasting, natural-looking results. Launching in Q2 2025, these products will seamlessly integrate with our fast-growing neurotoxin business, leveraging our strong customer relationships, innovative co-branded marketing, and competitive brand positioning. With a high overlap between the customer and consumer base for neurotoxins and fillers, Evolysse™ is perfectly positioned to drive significant value. Supported by one of the most extensive clinical trial programs in HA filler history, Evolysse™ products are being evaluated for safety and effectiveness in over 2,000 patients globally. This is just the beginning – we look forward to expanding the Evolysse™ collection with Evolysse™ Sculpt in 2026 and Evolysse™ Lips in 2027! Read the full press release: https://lnkd.in/eJctksm8 #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics
Evolus CEO David Moatazedi recently joined Oliver Renick on the Schwab Network to discuss our continued growth and the exciting road ahead. We have captured 13% market share with Jeuveau®, the fastest-growing neurotoxin in the U.S. for four consecutive years and are preparing to expand our portfolio with the upcoming launch of Evolysse™, our line of unique injectable hyaluronic acid (HA) gels. Evolysse™ represents the first breakthrough technological hashtag#innovation in the HA filler market in over a decade and is being evaluated in over 2,000 patients globally. With FDA approval expected in the next 90 days and a planned launch in Q2 2025, we are excited to bring this highly differentiated Cold-X™ technology to the cash-pay aesthetics market, strengthening our leadership in hashtag#performance beauty. As a company that has delivered over 30% revenue growth for five years, we are well-positioned to build on this momentum. With a strong foundation in place and a growing portfolio, we look forward to continuing to redefine aesthetics and drive long-term value for our customers and shareholders. https://lnkd.in/eZeqaSQM $EOLS hashtag#Evolus hashtag#EvolveWithUs hashtag#PerformanceBeauty hashtag#MedicalAesthetics
We're excited to announce that for the second year in a row, Evolus has made the @Deloitte Technology Fast 500, recognizing the fastest growing companies in North America! This achievement highlights the strength of our team, the success of our customer-focused strategy, and our commitment to innovation in performance beauty. #evolus #performancebeauty #aesthetics
Evolus announced our preliminary fourth quarter and full-year 2024 net revenue, achieving record results at the top of guidance. We also issued 2025 guidance, highlighting our momentum heading into the new year. With expected U.S. approval within 90 days for our new product line of unique injectable hyaluronic acid (HA) gels and a clear path to full-year profitability in 2025, we are poised for another year of exceptional growth. View the press release here: https://lnkd.in/eAtkQvya #EOLS
